2023/01/11 PHARMCUBE Colum
As one of the most important technologies in the field of life science in the 21st century, gene editing technology is gradually showing its application potential and vigorous development. According to the data, the global genome editing market is expected to reach $4.3 billion in 2022 and $12.8 billion in 2027. The global genome editing market is expected to grow at a compound annual growth rate of 24.7% in 2022-2027.
Following the successful holding of the first science and technology event, Sequoia Talk series Forum medical event recently came to a successful conclusion. In the gene editing session, Mr. Jiang Han, Director & General Manager of Sequoia China, and Dr. Xiaodun Mou, CEO of CorrectSequence Therapeutics (Correctseq), presented a wonderful sharing of cutting-edge gene editing technologies and innovative treatment solutions with the theme of "Turning Knife into Pen, Base Editing Leads Cell and Gene Therapy into Minimally Invasive Era".
Recently, CorrectSequence Therapeutics (Correctseq), a biotechnology company aims to use their own innovative gene editing system to help people living with serious diseases, announced that transformer Base Editor (tBE) developed independently is authorized by USPTO (United States Patent and Trademark Office) formally and became the Chinese first base editing tool authorized by overseas patents.
tBE(transformer Base Editor), developed by the scientific co-founders of CorrectSequence Therapeutics (Correctseq), is authorized by USPTO (United States Patent and Trademark Office) formally. It’s th
In face of tens of thousands of unsolved difficult diseases, gene editing technology known as "God's scalpel" is expected. Like turning knives into pens, several young Chinese scientists in Zhangjiang of Shanghai are committed to developing novel gene editors without making a double-stranded break in the DNA, directly modifying the wrong genetic information. In the trend of entrepreneurship, they want to develop the advanced gene editing technology into a precision genetic therapy of variety of genetic and tumor diseases as soon as possible.